{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:26:39Z","timestamp":1773887199386,"version":"3.50.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":34,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Informatics in Medicine Unlocked"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.imu.2021.100531","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T12:35:55Z","timestamp":1612960555000},"page":"100531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Identification of potential antivirals against SARS-CoV-2 using virtual screening method"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9220-0848","authenticated-orcid":false,"given":"Mohammad Rejaur","family":"Rahman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1243-2858","authenticated-orcid":false,"given":"Anik","family":"Banik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishtiak Malique","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emran Hossain","family":"Sajib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanchita","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imu.2021.100531_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.imu.2021.100531_bib2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/jama.2020.0757","article-title":"Coronavirus infections\u2014more than just the common cold","volume":"323","author":"Paules","year":"2020","journal-title":"JAMA, J Am Med Assoc"},{"key":"10.1016\/j.imu.2021.100531_bib3","doi-asserted-by":"crossref","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.imu.2021.100531_bib4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.imu.2021.100531_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/v11010056","article-title":"Potent MERS- CoV fusion inhibitory peptides identified from HR2 domain in spike protein of bat coronavirus HKU4","volume":"11","author":"Xia","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.imu.2021.100531_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01387-19","article-title":"Molecular basis of binding between Middle East respiratory syndrome coronavirus and CD26 from seven bat species","volume":"94","author":"Yuan","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.imu.2021.100531_bib7","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.imu.2021.100531_bib8","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.imu.2021.100531_bib9","series-title":"Coronavirus disease 2019 (COVID-19)\u2014Transmission","author":"CDC","year":"2020"},{"key":"10.1016\/j.imu.2021.100531_bib10","series-title":"How COVID-19 spreads","author":"CDC","year":"2020"},{"key":"10.1016\/j.imu.2021.100531_bib11","series-title":"Q&a on coronaviruses","author":"WHO","year":"2020"},{"key":"10.1016\/j.imu.2021.100531_bib12","series-title":"Coronavirus disease (COVID-2019) situation report-73","author":"WHO","year":"2020"},{"key":"10.1016\/j.imu.2021.100531_bib13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.imu.2021.100531_bib14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hos- pitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA, J Am Med Assoc"},{"key":"10.1016\/j.imu.2021.100531_bib15","unstructured":"COVID-19 dashboard by the center for systems science and engineering (CSSE) at Johns Hopkins University (JHU)\". ArcGIS. Johns Hopkins University. Retrieved 2 July 2020."},{"key":"10.1016\/j.imu.2021.100531_bib16","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1016\/j.vaccine.2020.04.034","article-title":"An effective CTL peptide vaccine for Ebola Zaire based on survivors' CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design","volume":"38","author":"Herst","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.imu.2021.100531_bib17","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(20)30763-7","article-title":"Ensuring global access to COVID-19 vaccines","volume":"395","author":"Yamey","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.imu.2021.100531_bib18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"BioSci Trends"},{"key":"10.1016\/j.imu.2021.100531_bib19","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.imu.2021.100531_bib20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID- 19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.imu.2021.100531_bib21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"AshburnandK","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.imu.2021.100531_bib22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/bib\/bbv020","article-title":"A survey of current trends in computational drug repositioning","volume":"17","author":"Li","year":"2016","journal-title":"Briefings Bioinf"},{"key":"10.1016\/j.imu.2021.100531_bib23","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.2174\/1381612822666160325121943","article-title":"Exploring polypharmacology in drug discovery and Repurposing using the CANDO platform","volume":"22","author":"Chopra","year":"2016","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.imu.2021.100531_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emi.2014.88","article-title":"Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs","volume":"3","author":"Kouznetsova","year":"2014","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.imu.2021.100531_bib25","doi-asserted-by":"crossref","first-page":"290ra89","DOI":"10.1126\/scitranslmed.aaa5597","article-title":"A screen of approved drugs and molecular probes identifies therapeutics with anti\u2013Ebola virus activity","volume":"7","author":"Johansen","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.imu.2021.100531_bib26","doi-asserted-by":"crossref","first-page":"282ra49","DOI":"10.1126\/scitranslmed.3010286","article-title":"Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection","volume":"7","author":"He","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.imu.2021.100531_bib27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.chom.2016.07.004","article-title":"A screen of FDA-approved drugs for inhibitors of Zika virus infection","volume":"20","author":"Barrows","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.imu.2021.100531_bib28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking","volume":"267","author":"Jones","year":"1997","journal-title":"J Mol Biol"},{"key":"10.1016\/j.imu.2021.100531_bib29","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.imu.2021.100531_bib30","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1021\/acs.jmedchem.5b02008","article-title":"Docking screens for novel ligands conferring new Biology","volume":"59","author":"Irwin","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.imu.2021.100531_bib31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/1875692116666181108145230","article-title":"Computational studies of molecular targets regarding the adverse effects of isoniazid drug for tuberculosis","volume":"16","author":"Mohanasundaram","year":"2018","journal-title":"Curr Pharmacogenomics Personalized Med (CPPM)"},{"key":"10.1016\/j.imu.2021.100531_bib32","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/j.ddtec.2012.07.009","article-title":"Insilico virtual screening approaches for anti-viral drug discovery","volume":"9","author":"Murgueitio","year":"2012","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.imu.2021.100531_bib33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/clpt.2013.1","article-title":"Computational drug repositioning: from data to therapeutics","volume":"93","author":"Hurle","year":"2013","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.imu.2021.100531_bib34","article-title":"The RCSB protein data bank: integrative view of protein, gene and 3D structural information","volume":"45","author":"Rose","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.imu.2021.100531_bib35","doi-asserted-by":"crossref","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","article-title":"PubChem substance and compound databases","volume":"44","author":"Kim","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.imu.2021.100531_bib36","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.imu.2021.100531_bib37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open Babel: an open chemical toolbox","volume":"3","author":"O'Boyle","year":"2011","journal-title":"J Cheminf"},{"key":"10.1016\/j.imu.2021.100531_bib38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/157340911795677602","article-title":"Molecular docking: a powerful approach for structure-based drug discovery","volume":"7","author":"Meng","year":"2011","journal-title":"Curr Comput Aided Drug Des"},{"key":"10.1016\/j.imu.2021.100531_bib39","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.3390\/ijms11083016","article-title":"Advances and challenges in protein-ligand docking","volume":"11","author":"Huang","year":"2010","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.imu.2021.100531_bib40","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/138620711795767866","article-title":"Integrating virtual screening and combinatorial chemistry for accelerated drug discovery","volume":"14","author":"L\u00f3pez-Vallejo","year":"2011","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1016\/j.imu.2021.100531_bib41","doi-asserted-by":"crossref","first-page":"W363","DOI":"10.1093\/nar\/gki481","article-title":"PatchDock and SymmDock: servers for rigid and symmetric docking","volume":"33","author":"Schneidman-Duhovny","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.imu.2021.100531_bib42","doi-asserted-by":"crossref","first-page":"100367","DOI":"10.1016\/j.imu.2020.100367","article-title":"Screening and druggability analysis of some plant metabolites against SARS- CoV-2: an integrative computational approach","volume":"20","author":"Azim","year":"2020","journal-title":"Inf Med Unlocked"},{"issue":"9","key":"10.1016\/j.imu.2021.100531_bib43","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.sjbs.2020.04.002","article-title":"In-silico elucidation of Moringaoleifera phytochemicals against diabetes mellitus","volume":"27","author":"Zainab","year":"2020","journal-title":"Saudi J Biol Sci"},{"key":"10.1016\/j.imu.2021.100531_bib44","series-title":"Identification of potential inhibitory analogs of metastasis tumor antigens (MTAs) using bioactive compounds: revealing therapeutic option to prevent malignancy","author":"Banik","year":"2020"},{"key":"10.1016\/j.imu.2021.100531_bib45","article-title":"Site-specific N-glycosylation characterization of recombinant SARS-CoV-2 spike proteins","author":"Zhang","year":"2020","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.imu.2021.100531_bib46","doi-asserted-by":"crossref","first-page":"W229","DOI":"10.1093\/nar\/gkn186","article-title":"FireDock: a web server for fast interaction refinement in molecular docking","volume":"36","author":"Mashiach","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.imu.2021.100531_bib47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.imu.2021.100531_bib48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jlumin.2015.03.025","article-title":"Interaction of \u03b1-cyperone with human serum albumin: determination of the binding site by using Discovery Studio and via spectroscopic methods","volume":"164","author":"Wang","year":"2015","journal-title":"J Lumin"},{"key":"10.1016\/j.imu.2021.100531_bib49","series-title":"CCP4 Newsletter on protein crystallography","first-page":"82","article-title":"Pymol: an open-source molecular graphics tool","volume":"40","author":"DeLano","year":"2002"},{"key":"10.1016\/j.imu.2021.100531_bib50","doi-asserted-by":"crossref","first-page":"W271","DOI":"10.1093\/nar\/gku339","article-title":"iMODS: internal coordinates normal mode analysis server","volume":"42","author":"L\u00f3pez-Blanco","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.imu.2021.100531_bib51","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/bib\/bbz141","article-title":"LARMD: integration of bioinformatic resources to profile ligand-driven protein dynamics with a case on the activation of estrogen receptor","volume":"21","author":"Yang","year":"2019","journal-title":"Briefings Bioinf"},{"issue":"1","key":"10.1016\/j.imu.2021.100531_bib52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1039\/C8MD00472B","article-title":"ADMET-score - a comprehensive scoring function for evaluation of chemical drug-likeness","volume":"10","author":"Guan","year":"2018","journal-title":"Med Chem Comm"},{"key":"10.1016\/j.imu.2021.100531_bib53","doi-asserted-by":"crossref","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.imu.2021.100531_bib54","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1021\/acs.jcim.6b00174","article-title":"SwissSimilarity: a web tool for low to ultra high throughput ligand-based virtual screening","volume":"56","author":"Zoete","year":"2016","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.imu.2021.100531_bib55","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00003495-200969040-00007","article-title":"Darunavir","volume":"69","author":"McKeage","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.imu.2021.100531_bib56","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2165\/00003495-199958060-00011","article-title":"Indinavir","volume":"58","author":"Plosker","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.imu.2021.100531_bib57","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00003088-199936020-00004","article-title":"Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir","volume":"36","author":"Cundy","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.imu.2021.100531_bib58","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/0006-2952(93)90610-9","article-title":"Metabolism of 5\u2032-ether prodrugs of 1-\u03b2-d-Arabinofuranosyl-E-5-(2-bromovinyl) uracil in rats","volume":"46","author":"Ashida","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.imu.2021.100531_bib59","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1128\/AAC.49.6.2314-2321.2005","article-title":"TMC114, a novel Angeles (CA) human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates","volume":"49","author":"De Meyer","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.imu.2021.100531_bib60","author":"Tibotec Therapeutics"},{"key":"10.1016\/j.imu.2021.100531_bib61","first-page":"378","article-title":"Studies on the metabolic fate of Brovavir (YN-72) II; metabolism in rats","volume":"21","author":"Nishimoto","year":"1990","journal-title":"IyakuhinKenkyu"},{"key":"10.1016\/j.imu.2021.100531_bib62","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0090-9556(25)07348-9","article-title":"Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor","volume":"24","author":"Chiba","year":"1996","journal-title":"Drug Metabol Dispos"},{"key":"10.1016\/j.imu.2021.100531_bib63","first-page":"552","article-title":"Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4\/3A5: mechanism-based in activation of cytochrome P4503A by ritonavir","volume":"26","author":"Koudriakova","year":"1998","journal-title":"Drug Metabol Dispos"},{"key":"10.1016\/j.imu.2021.100531_bib64","series-title":"American Hospital formulary service - drug information 2003","author":"McEvoy","year":"2003"},{"key":"10.1016\/j.imu.2021.100531_bib65","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0090-9556(25)08479-X","article-title":"Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans","volume":"24","author":"Balani","year":"1996","journal-title":"Drug Metabol Dispos"},{"key":"10.1016\/j.imu.2021.100531_bib66","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00003495-199958020-00015","article-title":"Cidofovir","volume":"58","author":"Plosker","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.imu.2021.100531_bib67","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/095632020001100202","article-title":"Synthesis and anti-HIV activity of prodrugs derived from saquinavir and indinavir","volume":"11","author":"Far\u00e8se-Di Giorgio","year":"2000","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.imu.2021.100531_bib68","series-title":"LiverTox: clinical and research information on drug-induced liver injury","year":"2012"},{"key":"10.1016\/j.imu.2021.100531_bib69","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1053\/ajkd.2001.27732","article-title":"Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors","volume":"38","author":"Reilly","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.imu.2021.100531_bib70","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MOO.0b013e3282f43408","article-title":"Cidofovir: to use or not to use?","volume":"16","author":"Soma","year":"2008","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.imu.2021.100531_bib71","series-title":"LiverTox: clinical and research information on drug-induced liver injury","year":"2012"},{"key":"10.1016\/j.imu.2021.100531_bib72","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/j.1348-0421.1997.tb01955.x","article-title":"Metabolic fate of [3H] 1-\u03b2-D-arabinofuranosyl-5-[(E)-2-bromovinyl] uracil in herpes simplex virus type 1-infected cells","volume":"41","author":"Ashida","year":"1997","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.imu.2021.100531_bib73","series-title":"Concepts and applications of molecular similarity","author":"Johnson","year":"1990"},{"key":"10.1016\/j.imu.2021.100531_bib74","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1021\/jm020155c","article-title":"Do structurally similar molecules have similar biological activity?","volume":"45","author":"Martin","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.imu.2021.100531_bib75","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1021\/jm060655w","article-title":"Identification of natural-product-derived inhibitors of 5- lipoxygenase activity by ligand-based virtual screening","author":"Franke","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.imu.2021.100531_bib76","doi-asserted-by":"crossref","first-page":"19256","DOI":"10.1073\/pnas.0707130104","article-title":"Protein\u2212protein interaction inhibition (2P2I) combining high throughput and virtual screening: application to the HIV-1 Nefprotein","volume":"104","author":"Betzi","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.imu.2021.100531_bib77","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.drudis.2006.10.005","article-title":"Similarity-based virtual screening using 2D fingerprints","volume":"11","author":"Willett","year":"2006","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.imu.2021.100531_bib78","doi-asserted-by":"crossref","first-page":"17278","DOI":"10.1073\/pnas.0805820105","article-title":"Discovery of drug-like inhibitors of an essential RNAediting ligase in Trypanosomabrucei","volume":"105","author":"Amaro","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.imu.2021.100531_bib79","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1021\/ci400100c","article-title":"Scaffold-focused virtual screening: prospective application to the discovery of TTK inhibitors","volume":"53","author":"Langdon","year":"2013","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.imu.2021.100531_bib80","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov Therapeut"},{"key":"10.1016\/j.imu.2021.100531_bib81","first-page":"1","article-title":"Clinical trials on drug repositioning for COVID- 19 treatment","volume":"44","author":"Rosa","year":"2020","journal-title":"RevistaPanamericana de SaludP\u00fablica"},{"key":"10.1016\/j.imu.2021.100531_bib82","article-title":"Virtual Screening based prediction of potential drugs for COVID-19","volume":"23","author":"Sekhar","year":"2020","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1016\/j.imu.2021.100531_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011955","article-title":"Virtual screening for HIV protease inhibitors: a comparison of AutoDock 4 and Vina","volume":"5","author":"Chang","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.imu.2021.100531_bib84","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1099\/vir.0.19424-0","article-title":"Mechanisms and enzymes involved in SARS coronavirus genome expression","volume":"84","author":"Thiel","year":"2003","journal-title":"J Gen Virol"},{"key":"10.1016\/j.imu.2021.100531_bib85","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CMR.00102-14","article-title":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease","volume":"28","author":"Chan","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.imu.2021.100531_bib86","doi-asserted-by":"crossref","first-page":"10598","DOI":"10.1073\/pnas.1932511100","article-title":"The entry of entry inhibitors: a fusion of science and medicine","volume":"100","author":"MooreandR","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.imu.2021.100531_bib87","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.aivir.2019.08.002","article-title":"Structural insights into coronavirus entry","volume":"105","author":"Tortorici","year":"2019","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.imu.2021.100531_bib88","series-title":"A taxonomically-driven approach to development of potent, broad-spectrum inhibitors of coronavirus main protease including SARS-CoV-2 (COVID-19)","author":"Mesecar","year":"2020"},{"key":"10.1016\/j.imu.2021.100531_bib89","doi-asserted-by":"crossref","first-page":"101258","DOI":"10.1016\/j.isci.2020.101258","article-title":"Crystal structure of the SARS-CoV-2 non-structural protein 9, Nsp9","volume":"23","author":"Littler","year":"2020","journal-title":"Iscience"},{"key":"10.1016\/j.imu.2021.100531_bib90","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc Natl Acad Sci Unit States Am"},{"key":"10.1016\/j.imu.2021.100531_bib91","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1023\/A:1008629608556","article-title":"Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir","volume":"19","author":"Hoetelmans","year":"1997","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.imu.2021.100531_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2125.1998.00050.x","article-title":"Sorivudine and 5\u2010fluorouracil; a clinically significant drug\u2010drug interaction due to inhibition of dihydropyrimidine dehydrogenase","volume":"46","author":"Diasio","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.imu.2021.100531_bib93","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0213-005X(08)76547-9","article-title":"Chemical characteristics, mechanism of action and antiviral activity of darunavir","volume":"26","author":"Pasquau","year":"2008","journal-title":"Enferm Infecc Microbiol Cl\u00edn"},{"key":"10.1016\/j.imu.2021.100531_bib94","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1128\/AAC.00055-12","article-title":"Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing","volume":"56","author":"Davis","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.imu.2021.100531_bib95","series-title":"Handbook of computational chemistry","first-page":"1","article-title":"Predicting ADME properties of chemicals","author":"Shin","year":"2017"},{"key":"10.1016\/j.imu.2021.100531_bib96","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1517\/17425250903282773","article-title":"Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application","volume":"5","author":"Kieback","year":"2009","journal-title":"Expet Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.imu.2021.100531_bib97","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1081\/PDT-200031432","article-title":"Topical liposomal gel of idoxuridine for the treatment of herpes simplex: pharmaceutical and clinical implications","volume":"9","author":"Seth","year":"2005","journal-title":"Pharmaceut Dev Technol"},{"key":"10.1016\/j.imu.2021.100531_bib98","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1586\/eri.09.6","article-title":"Treatment of chronic hepatitis B: focus on telbivudine","volume":"7","author":"LuiandH","year":"2009","journal-title":"Expert Rev Anti-infect Ther"},{"key":"10.1016\/j.imu.2021.100531_bib99","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1742-6405-5-5","article-title":"Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir\/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT","volume":"5","author":"Smith","year":"2008","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.imu.2021.100531_bib100","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1128\/AAC.43.7.1686","article-title":"Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults","volume":"43","author":"Sadler","year":"1999","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Informatics in Medicine Unlocked"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352914821000216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352914821000216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:20:53Z","timestamp":1762492853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352914821000216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":100,"alternative-id":["S2352914821000216"],"URL":"https:\/\/doi.org\/10.1016\/j.imu.2021.100531","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv.12923684.v1","asserted-by":"object"}]},"ISSN":["2352-9148"],"issn-type":[{"value":"2352-9148","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of potential antivirals against SARS-CoV-2 using virtual screening method","name":"articletitle","label":"Article Title"},{"value":"Informatics in Medicine Unlocked","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imu.2021.100531","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100531"}}